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A B S T R A C T
Background
Abnormal biliary secretion leads to the thickening of bile and the formation of plugs within the bile ducts; the consequent obstruction
and abnormal bile flow ultimately results in the development of cystic fibrosis-related liver disease. This condition peaks in adolescence
with up to 20% of adolescents with cystic fibrosis developing chronic liver disease. Early changes in the liver may ultimately result in
end-stage liver disease with people needing transplantation. One therapeutic option currently used is ursodeoxycholic acid. This is an
update of a previous review.
Objectives
To analyse evidence that ursodeoxycholic acid improves indices of liver function, reduces the risk of developing chronic liver disease
and improves outcomes in general in cystic fibrosis.
Search methods
We searched the Cochrane CF and Genetic Disorders Group Trials Register comprising references identified from comprehensive
electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. We also contacted drug
companies and searched online trial registries.
Date of the most recent search of the Group’s trials register: 09 April 2017.
Selection criteria
Randomised controlled trials of the use of ursodeoxycholic acid for at least three months compared with placebo or no additional
treatment in people with cystic fibrosis.
Data collection and analysis
Two authors independently assessed trial eligibility and quality. The authors used GRADE to assess the quality of the evidence.
Main results
Twelve trials have been identified, of which four trials involving 137 participants were included; data were only available from three of
the trials (118 participants) since one cross-over trial did not report appropriate data. The dose of ursodeoxycholic acid ranged from
10 to 20 mg/kg/day for up to 12 months. The complex design used in two trials meant that data could only be analysed for subsets of
participants. There was no significant difference in weight change, mean difference -0.90 kg (95% confidence interval -1.94 to 0.14)
based on 30 participants from two trials. Improvement in biliary excretion was reported in only one trial and no significant change after
treatment was shown. There were no data available for analysis for long-term outcomes such as death or need for liver transplantation.
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Authors’ conclusions
There are few trials assessing the effectiveness of ursodeoxycholic acid. The quality of the evidence identified ranged from low to very
low. There is currently insufficient evidence to justify its routine use in cystic fibrosis.
P L A I N L A N G U A G E S U M M A R Y
Ursodeoxycholic acid for liver disease related to cystic fibrosis
Review question
Does ursodeoxycholic acid improve measures of liver function, reduce the risk of developing chronic liver disease and improve outcomes
in general in people with cystic fibrosis?
Background
Problems with the consistency of bile (thickened) and how it flows cause liver disease in up to 20% of young people with cystic fibrosis.
Bile ducts can become blocked and cause cirrhosis in one or more parts of the liver. Ursodeoxycholic acid is a naturally occurring bile
acid which is taken as either a tablet or liquid to try and prevent liver disease in people with cystic fibrosis. The best response seems
to be from a total dose of 20 mg/kg/day in two to three separate doses and given initially for several months but possibly indefinitely.
Originally it was used to treat gallstones, but over the last few years it has been used to treat and prevent the progression of cystic
fibrosis-related liver disease. This is an updated version of the review.
Search date
We last searched for evidence on 09 April 2017.
Study characteristics
We searched for trials of ursodeoxycholic acid lasting for at least three months and were able to include four trials, but data for analysis
were only available from three of these. There are data from 118 participants aged between four and 32 years in this review. The dose
of the drug given in the three trials with data ranged from 10 to 20 mg/kg/day. Two of these trials compared ursodeoxycholic acid to
tablets with no medicine in them (placebo) and the third trial compared ursodeoxycholic acid to ’usual’ treatment. The complex design
of two trials meant data could not be analysed for all the participants. The trials lasted for up to 12 months, but no longer; however,
one trial did report some follow-up data after nine years.
Key results
Not many of the outcomes we listed in our review were assessed; only weight gain, skinfold thickness and biliary excretion. There were
no real differences between treatments for any of these outcomes. Long-term outcomes that we think are important, such as death or
the need for liver transplant, were only reported in the follow-up of one trial and the information did not tell us if the people who died
or needed a liver transplant had received ursodeoxycholic acid or placebo.
Current research shows that side effects of this treatment are rare, but there is not enough information about using it in the long-term
to justify routinely giving it to people with cystic fibrosis. As there is no other treatment to prevent liver disease, more research on
ursodeoxycholic acid is needed.
Quality of the evidence
The trials seemed to be well organised and well run, but there was not always enough information to judge them properly. While, on
the whole, we do not think that any factors linked to how the trials were run would influence the results greatly, we did have some
concerns that in one trial the group taking ursodeoxycholic acid were generally not as healthy at the start of the trial as the group taking
placebo. Also, in another trial there were some people who withdrew and were not included in the final analysis, but no reasons for this
were given. Overall, we judged the quality of the evidence we found to be low or very low.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Ursodeoxycholic acid compared with control for cystic fibrosis- related liver disease
Patient or population: adults and children with cyst ic f ibrosis-related liver disease
Settings: outpat ients
Intervention: ursodeoxycholic acid (UDCA)
Comparison: control (placebo or convent ional care (i.e. no addit ional treatment))
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(trials)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control UDCA
Change of hepatocellu-
lar enzymes1
Follow-up: 6 months
There were no signif icant dif f erences between
UDCA and control in terms of normalisat ion of
all, any or individual liver enzymes
NA 16
(2 trials)
⊕©©©
very low2,3
Abnormally large liv-
ers reduced to within
normal limits, as mea-
sured by ultrasound
Follow-up: NA
Outcome not reported NA
Need for liver trans-
plantation
Follow-up: up to 12
months
No part icipants in any
of the included trials re-
ceived a liver transplant
1 part icipant was with-
drawn f rom one of the
included trials and sub-
sequent ly received a
liver transplant
NA 58
(3 trials)
⊕©©©
very low2,3
The outcome ’Need
for liver transplanta-
t ion’ was not specif -
ically reported. Infor-
mation regarding how
many individuals in
each trial received liver
transplants was avail-
able
Long-term data f rom
one trial (Colombo
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1996) showed that six
part icipants across the
ent ire cohort received a
liver transplant
Mortality
Follow-up: up to 12
months
There were no deaths in either treatment group
(related to liver disease or all causes) in any of
the trials
NA 58
(3 trials)
⊕⊕©©
low2
Long-term data f rom
one trial (Colombo
1996) showed that 13
part icipants across the
ent ire cohort died.
Nutritional status:
change in weight (kg)
Follow-up: 6 months
The mean change in
weight ranged across
control groups f rom
0.83 to 4.88 kg
The mean change in
weight was in the UDCA
groups was 0.90 kg
lower (1.94 kg lower to
0.14 kg higher)
NA 30
(2 trials)
⊕⊕©©
low2
Minor variat ions (im-
provements) in skin-
fold thickness and body
mass percent ile data
were also reported in
both trials but no dif fer-
ences across treatment
groups were mentioned
Development of portal
hypertension
Follow-up: 6 months
No part icipants in either treatment group de-
veloped portal hypertension or complicat ions of
portal hypertension in any of the trials
NA 30
(2 trials)
⊕⊕©©
low2
Improved abnormal bil-
iary excretion
Follow-up: 6 months
There was no signif icant change in biliary excre-
t ion af ter treatment with UDCA
NA 12
(1 trial)
⊕⊕©©
low4,5
Measured in the in-
cluded trial as the t ime
(in minutes) f rom in-
ject ion of the isotope
to maximal hepat ic ac-
t ivity and the percent-
age clearance of iso-
tope f rom the liver and
biliary tree, at 45 and 60
minutes compared with
maximal act ivity
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* The basis for the assumed risk (e.g. the median control group risk across trials) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based
on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; NA: not applicable
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Def ined as ’Change f rom outside the normal range on at least one occasion to within the normal range of the method
stated.’
2. Downgraded twice due to serious risk of bias: one trial was judged to be at high risk of attrit ion bias due to large amounts
of incomplete outcome data and all included trials did not report clear details regarding trial design.
3. Downgraded once due to imprecision: very wide CIs around some ef fect sizes due to low event rates.
4. Downgraded once due to risk of bias: the included trial did not report clear details regarding trial design.
5. Downgraded once due to imprecision: numerical results for the outcome not available
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B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is a common inherited disease which invari-
ably leads to progressive lung damage. The medical management
of associated chronic chest disease has improved greatly over the
last 30 years leading to improvement in survival well into adult
life. Clinicians are now examining ways of both treating and delay-
ing the progression of the disease in other affected organs. Among
these, CF-related liver disease is clinically themost significant hep-
atic complication with a large impact on morbidity and mortality
(Leeuwen 2014). A recent review suggested that hepatobiliary dis-
ease is themost common non-pulmonary cause of mortality in CF
(the third after pulmonary disease and transplant complications)
(Parisi 2013). A recent epidemiological study reported that there
was a significantly higher prevalence of CF-related hepatobiliary
abnormalities in people with CF under 18 years of age and 25%
of those with CF-related hepatobiliary abnormalities developed
hepatobiliary disease (Bhardwaj 2009).
The mechanism of liver involvement in CF is thought to be due to
a chloride channel defect causing abnormal biliary secretion which
leads to the thickening of bile and the formationof plugswithin the
bile ducts. The resulting ductular obstruction and abnormal bile
flowultimately results in the development of bile duct irregularities
inside and outside the liver and cirrhosis in one or several parts of
the liver. Therefore, therapy has been directed towards attempting
to improve biliary secretion and bile acid composition.
Description of the intervention
Ursodeoxycholic acid (UDCA) is a naturally occurringhydrophilic
bile acid.
It is usual to take UDCA by mouth twice or three times a day,
initially for several months but possibly indefinitely. Side effects
are rare but diarrhoea has been reported. In 2003, the cost of six
months’ (24 weeks) treatment with UDCA for a 10-year old child
weighing 25 kg, at a dose of 20 mg/kg/day, was £131 (RLCH
2003). Colombo demonstrated in a dose-response study that the
biochemical response to UDCA was best with a dose of 20 mg/
kg/day (Colombo 1992).
How the intervention might work
In 1990, Erlinger showed that UDCA improves bile acid flow by
inducing a bicarbonate-rich bile flow (Erlinger 1990). This mech-
anism has potential use for people with CF-related liver disease in
whom the bile ducts are blocked by thick and sticky secretions.
Also, UDCA is not as toxic to the liver as other primary bile acids.
Initially, UDCA was used in the treatment of gallstones (Roda
1982) and more recently as a possible treatment for other chronic
liver diseases such as primary biliary cirrhosis (Poupon 1991) and
primary sclerosing cholangitis (Beuers 1992). Over the last few
years it has been used in the treatment and prevention of progres-
sion of CF-related liver disease following the observation of its
therapeutic effectiveness in these other cholestatic conditions.
Why it is important to do this review
There are a number of debates surrounding the treatment of peo-
ple with CF who have liver involvement. Both early detection and
assessment of progression of liver disease in CF are relatively dif-
ficult. This is because by the time liver disease is evident in a per-
son with an enlarged liver or spleen, there is often already raised
pressure in the large vein running through the liver (portal hyper-
tension, usually an irreversible event) and end-stage liver damage
(cirrhosis). At this stage the only helpful treatment may be a liver
transplant. These problemsmean that clinicians are faced with the
dilemma of when UDCA should be commenced: early to prevent
liver involvement; or later as a therapeutic option.
Another debate is how liver involvement can be evaluated. The
important outcomes are death and preventing liver transplanta-
tion; other surrogate markers are often used but there are prob-
lems associated with these. Biochemical measures of liver function
may not be useful because the level of abnormality does not al-
ways correlate with the extent of liver involvement (Tanner 1992).
Abnormalities of these test results may also be due to an effect
other than CF liver disease, such as an effect of a drug treatment
(Tanner 1992). Ultrasound can be used to assess the presence and
progression of liver disease (Carty 1995). It can show alterations in
liver size and texture and can also be used to assess the extent and
direction of blood flow in the portal vein. However, results may
vary with different operators. Another technique for identifying
liver disease is radioisotope scanning (hepatobiliary scintigraphy)
(O’Connor 1996). Measuring the hepatic excretion of the com-
pound 99mTc-HIDA allows an objective measurement of liver
function and bile acid secretion. However, these are all interme-
diate outcomes and their correlations with the outcomes of death
and liver transplantation are unknown.
AlthoughUDCA is relatively inexpensive compared to other treat-
ments taken by people with CF (see above), it is yet another treat-
ment of many and it is important that it has been shown to be
effective. Therefore, we have undertaken a systematic review as-
sessing its effectiveness in people with CF with liver involvement.
This is an updated version of earlier versions of the review (Cheng
1997; Cheng 1999; Cheng 2012; Cheng 2014).
O B J E C T I V E S
To analyse evidence from randomised controlled trials (RCTs) in
CF that UDCA improves indices of liver function, reduces the
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risk of developing chronic liver disease and improves outcomes in
general in CF.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs (published or unpublished). Trials where pseudo-randomi-
sation methods are used, such as alternation, will be included.
Types of participants
Children and adults with defined CF, diagnosed clinically and
by sweat test or genetic testing, including all ages, all degrees of
severity of disease and any degree of liver involvement.
Types of interventions
UDCA administered orally, at any dose, given for a period of at
least three months compared to a control group receiving either
placebo or no additional therapy (i.e. both groups receiving usual
CF therapy).
Types of outcome measures
Primary outcomes
1. Change of hepatocellular enzymes from outside the normal
range on at least one occasion to within the normal range of the
method stated
2. Abnormally large livers reduced to within normal limits, as
measured by ultrasound
3. Need for liver transplantation
Secondary outcomes
1. Mortality
2. Weight gain, body mass index, z score (a measure of
nutritional status, where weight is expressed as a percentage of
ideal for height and then compared to the standard deviation for
the population (Frisancho 1990)) and other indices of
nutritional improvement, if reported
3. Development of portal hypertension shown by an enlarged
spleen (increased by at least 15%), direction of portal vein flow,
portal vein flow velocity, oesophageal varices (using ultrasound)
or the complications of portal hypertension - these may include
haematemesis (vomiting blood), reduction in platelet count or a
reduction in white cell count
4. Improved abnormal biliary excretion as documented by
isotope scanning (hepatic scintigraphy)
Search methods for identification of studies
We searched for all relevant published and unpublished trials with-
out restrictions on language, year or publication status.
Electronic searches
Relevant trials were identified from the Group’s Cystic Fibrosis
Trials Register using the terms liver AND ursodeoxycholic acid.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of the Cochrane Library),
weekly searches ofMEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching the abstract books of three major cystic fibrosis con-
ferences: the International Cystic Fibrosis Conference; the Euro-
pean Cystic Fibrosis Conference and the North American Cystic
Fibrosis Conference. For full details of all searching activities for
the register, please see the relevant section of the Cochrane Cystic
Fibrosis and Genetic Disorders Group’s website.
Date of the most recent search of the Group’s Cystic Fibrosis Trials
Register: 09 April 2017.
The authors searched clinicaltrials.gov (https://clinicaltrials.gov/)
and WHO ICTRP http://apps.who.int/trialsearch/ using the
terms ’cystic fibrosis’ AND ’ursodeoxycholic acid’.
Date of the most recent search: 13 April 2017.
Searching other resources
Reference sections of any trials identified were checked for any
further RCTs. In addition we undertook full text searching of
theJournal of Pediatrics from 1988 to 1995. We also contacted the
pharmaceutical companies that market UDCA: Hoechst Marion
Roussel (Destolit®) and Consolidated Chemicals Ltd (Ursofalk
®).
Data collection and analysis
Selection of studies
The two authors (KC andRS) independently applied the inclusion
criteria to all potential reports.
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Data extraction and management
We attempted to extract data from each RCT from the text, tables
and figures. We recorded data on the number of participants with
each outcome event, by allocated group, irrespective of compliance
and whether or not the participant was later thought to be eligible
or otherwise excluded from treatment or followup. For continuous
outcomes we recorded the mean change from baseline for each
group and standard error or standard deviation.
Assessment of risk of bias in included studies
In order to assess the risk of bias in the included trials, we consid-
ered such aspects as generation of randomisation sequence and al-
location concealment. If we regarded these as adequate then there
was a low risk of bias to the trial; if we regarded these as inadequate,
then there was a high risk of bias to the trial; and if they were
considered unclear then the risk of bias was unclear too. We also
considered the degree of blinding and the risk of bias increased as
the number of people blinded to the intervention decreased. We
also considered other risks of bias, e.g. from selective reporting.
Measures of treatment effect
We calculated a pooled estimate of the treatment effect for each
outcome across trials. For binary outcomes we calculated, where
possible, the odds of an outcome among treatment-allocated par-
ticipants to the corresponding odds among controls. For contin-
uous outcomes, where data were available, we calculated a pooled
estimate of treatment effect by calculating the mean difference
(MD) and 95% confidence intervals (CIs).
Unit of analysis issues
Althoughwe did not specifically excluded cross-over trials, we were
concerned about the use of a cross-over design. This was because
there may be a carry-over effect of UDCA in the control arm.
We did include one cross-over trial in this review (Merli 1994).
The data presented in the published report appeared to be com-
bined from both treatment periods, but the authors attempted to
overcome a possible carry-over effect of UDCA by using a one-
month washout period. However, we considered it appropriate to
compare only the first six months of the trial, i.e. UDCA versus
placebo. Data from the first period were not available in the pub-
lished report but the authors kindly provided the raw data. In-
cluding data from the first period in cross-over trials in meta-anal-
yses is not without problems. Excluding later periods loses some
of the information collected. Furthermore, if data from the first
period are available in published reports they are likely to represent
a biased subset of trials, usually because the authors have found
evidence of carry-over (Elbourne 2002).
Dealing with missing data
Where sufficient data were not available in the published reports
or the abstract of the conference proceedings, the review authors
attempted to contact the first and last authors of the paper.
We recorded data on the number of participants with each out-
come event, by allocated group, irrespective of compliance and
whether or not the participant was later thought to be eligible or
otherwise excluded from treatment or follow up. This approach
permits an intention-to-treat analysis.
Assessment of heterogeneity
We tested for heterogeneity between trial results using a standard
Chi² test.
Data synthesis
We analysed the data using a fixed-effect model. If, in future up-
dates of this review, we identify a moderate to large degree of het-
erogeneity, we will analyse the data using a random-effects model.
Subgroup analysis and investigation of heterogeneity
For future updates, if heterogeneity is identified and there are suf-
ficient trials included in the review, we plan to investigate hetero-
geneity by means of examining individuals with evidence of liver
disease at randomisation separately from those without liver dis-
ease.
Sensitivity analysis
Wewill also examine the robustness of our results using a sensitivity
analysis including and excluding trials with a high risk of bias.
Summary of findings and quality of the evidence
(GRADE)
In a post hoc change in line with current Cochrane guidance, at
the 2017 update we added a summary of findings table (Summary
of findings for the main comparison). We selected the following
seven outcomes to report (chosen based on relevance to clinicians
and consumers).
1. Change of hepatocellular enzymes from outside the normal
range on at least one occasion to within the normal range of the
method stated
2. Abnormally large livers reduced to within normal limits, as
measured by ultrasound
3. Need for liver transplantation
4. Mortality
5. Nutritional status
6. Development of portal hypertension
7. Improved abnormal biliary excretion
We determined the quality of the evidence using the GRADE ap-
proach; and downgraded evidence in the presence of a high risk of
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bias in at least one trial, indirectness of the evidence, unexplained
heterogeneity or inconsistency, imprecision of results, high prob-
ability of publication bias. We downgraded evidence by one level
if they considered the limitation to be serious and by two levels if
very serious.
R E S U L T S
Description of studies
Results of the search
Twelve trials have been identified as potentially relevant. Four trials
were included (Colombo 1996; Lepage 1997;Merli 1994;O’Brien
1992) and eight trials were excluded (Bittner 1989; Colombo
1992; Kapustina 2000; Narckewicz 1994; NCT00004315;
NCT00004441; Spray 2000; Van de Meeberg 1997).
Included studies
Four trials meet the inclusion criteria (Colombo 1996; Lepage
1997; Merli 1994; O’Brien 1992). One included trial is of cross-
over design but from the full published paper it is unclear whether
there was any washout period employed and furthermore, data are
not published for the first six-month period of the trial; thus we are
unable to extract appropriate data for analysis (Lepage 1997). As
such, we are only able to present results from three trials (Colombo
1996; Merli 1994; O’Brien 1992).
Four trials with a total of 137 participants are included in the
review, but results are only available from three trials involving a
total of 118 participants (Colombo 1996; Merli 1994; O’Brien
1992). The ages of the participants ranged from 4 years to 32
years. The dose of UDCA given ranged from 10 to 20 mg/kg/day.
In three trials the comparison was with placebo (Colombo 1996;
Lepage 1997; Merli 1994). In the fourth trial the comparison was
with existing conventional therapy (O’Brien 1992). In three of
the trials all of the participants had liver disease (Colombo 1996;
Lepage 1997; O’Brien 1992), whereas in the third trial only 10
out of 51 participants had liver disease (Merli 1994).
The length of follow-up was generally short and ranged from six
months (Merli 1994; O’Brien 1992) to 12 months (Colombo
1996; Lepage 1997).
Important long-term outcomes such as death or the need for liver
transplant were not reported. Only two of our protocol-defined
outcomes were assessed: the nutritional indices (weight gain and
skinfold thickness (Merli 1994; O’Brien 1992)); and biliary ex-
cretion (O’Brien 1992).
Trial design was complicated in three trials (Colombo 1996;
Lepage 1997; Merli 1994).
In the Merli cross-over trial, 51 participants were randomised to
receive UDCA alone or with taurine for six months and then
each treatment group was compared with a six-month placebo
period (Merli 1994). The sequence of treatment and placebo was
then randomised in a cross-over design. The data presented in the
published report of the cross-over RCT appeared to be combined
from both treatment periods. Although we had not specifically
excluded cross-over trials, we were concerned about the use of a
cross-over design. This was because theremay be a carry-over effect
of UDCA in the control arm, although the authors attempted to
overcome this by using a one-month washout period. However, we
considered it appropriate to compare only the first six months of
the trial, i.e. UDCA versus placebo.Data from the first periodwere
not available in the published report but the authors have kindly
provided the rawdata. Including data from the first period in cross-
over trials in meta-analyses is not without problems. Excluding
later periods loses some of the information collected. Furthermore,
if data from the first period are available in published reports they
are likely to represent a biased subset of trials, usually because the
authors have found evidence of carry-over (Elbourne 2002).
In a further cross-over trial we were unable to ascertain whether
a washout period was employed and data were not presented for
the first treatment period; we have not been able to clarify this
information and have therefore decided not to present any results
from this trial (Lepage 1997).
A factorial parallel design was employed in the Colombo trial
(Colombo 1996). In this multicentre trial, 55 participants were
randomised to receive UDCA or placebo and then each group was
further randomised to receive either taurine or a second placebo.
In effect, four parallel groups were studied.
In the O’Brien trial, 12 participants were randomised to UDCA
or no additional therapy for six months (other than usual CF treat-
ments, such as pancreatic enzymes and oral calorie supplements,
which the UDCA group also received) (O’Brien 1992). Advanced
liver disease, as documented by portal hypertension or histological
features of fibrosis or cirrhosis or all three, was present in 11 out
of 12 participants.
The use of taurine in two trials also complicated their design and
analysis since taurinemay affect liver involvement inCF (Colombo
1996; Merli 1994). Although UDCA is known to cause taurine
depletion, the combined effect of UDCA and taurine on liver
function is unknown.
These possible interactions and the complex trial designs caused
difficulties when we considered combining the data.We have used
subsets of the sample sizes given in the ’Characteristics of included
studies’ table so the participant numbers evaluated in the data ta-
bles and figures do not always tally with the sample sizes. In the
Merli cross-over trial we decided only to use data from the first six
months of the UDCA/placebo group and not use the UDCA plus
taurine group (Merli 1994). This gave us data on an unbalanced
number of participants in the two groups in the first six-month
period: only six participants in the UDCA group and 12 partici-
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pants in the control group (51 were initially randomised). In the
factorial, parallel trial we decided not to use data from participants
who received taurine (hence the total number of participants used
in the data tables was 28 not 55) (Colombo 1996). However, only
four of these 18 participants in this subset had abnormal liver en-
zymes at baseline.
Another issue of the Merli cross-over RCT was that although
weight, height and body mass percentile were measured, we had
concerns about this type of trial design (Merli 1994). We would
expect there to be a period effect on variables such as weight and
height and this would require more subtle analysis. Again, we de-
cided to use data only fromparticipants in theUDCA-alone group
and from the first six months of the trial before cross over.
In 2005, Colombo presented follow-up survival data (obtained
by a data collection form sent to each centre) from the RCT that
had been conducted in 1990 (Colombo 1996). Information was
obtained from 53 of the original 55 participants (two were lost to
follow-up) for a median total period of follow-up of 13.6 years;
follow-up data for the whole cohort were presented, not by ran-
domised group. The majority of the trial participants had contin-
ued open UDCA therapy after the end of the trial (median daily
dose 666 mg).
Excluded studies
Eight trials were excluded in total. Three trials were excluded be-
cause they did not include a placebo arm or a ’no UDCA’ arm
(Colombo 1992; NCT00004441; Van de Meeberg 1997). One
trial was not an RCT (Narckewicz 1994). Two trials were of in-
sufficient duration; in one the duration of follow up was only six
weeks (Bittner 1989) and in the final cross-over trial each treat-
ment arm lasted four weeks (NCT00004315). Two trials were
only published as abstracts (no full papers) with insufficient detail
to confirm they meet the inclusion criteria; given the age of the
abstracts, it is unlikely that any further publications relating to
this trial will be forthcoming and therefore the trials have been
excluded (Kapustina 2000; Spray 2000).
Risk of bias in included studies
Allocation
All four trials were described as randomised, but only one trial
stated the method used (Colombo 1996).We therefore judged the
Colombo trial to have a low risk of bias (Colombo 1996), and the
remaining three trials to have an unclear risk of bias (Lepage 1997;
Merli 1994; O’Brien 1992).
Two trials described how allocation was concealed and these were
judged to be adequate and hence have a low risk of bias (Colombo
1996; O’Brien 1992). The remaining two trials did not discuss
allocation concealment and so were judged to have an unclear risk
of bias (Lepage 1997; Merli 1994).
Blinding
One of the trials was described as double-blinded and we judged
this to have a low risk of bias (Colombo 1996). In the Merli trial,
glucose tablets were used as the placebo, so it is probable, although
not explicitly stated, that the participants at least were blinded
to whether they were in the treatment or control group, due to
this uncertainty we judged this to have an unclear risk of bias
(Merli 1994). The Lepage trial did not describe the placebo or any
other aspect of blinding so it was not possible to ascertain whether
the participants or the trial personnel were blinded to treatment
groups and this trial was also judged to have an unclear risk of
bias (Lepage 1997). It was not possible to blind the O’Brien trial
to participants or clinicians since the participants either received
UDCA or no additional treatment, it was not discussed whether
outcome assessors were blinded; and we therefore judged this trial
to have a unclear risk of bias (O’Brien 1992).
Incomplete outcome data
An intention-to-treat analysis was performed in two trials (low
risk of bias) (Colombo 1996; O’Brien 1992). In one trial 51 par-
ticipants were initially recruited, but nine subsequently withdrew
(Merli 1994). These participants were not followed up and were
not included in the analysis; data from a further two participants
were identified as being lost when the rawdatawere provided (high
risk of bias). In the fourth trial six out of 19 participants withdrew;
reasons were given for all six (unclear risk of bias) (Lepage 1997).
Other potential sources of bias
In the Colombo trial the characteristics of the two groups were
not equal at baseline; the paper states that all five participants
with oesophageal varices and seven out of eight participants with
abnormal serum bilirubin levels at entry were allocated to the
UDCA group (high risk of bias) (Colombo 1996). One cross-over
trial does not clearly report whether there was any washout period
and data are not published for the first six-month period of the
trial (unclear risk of bias) (Lepage 1997). For the remaining two
trials no other potential sources of bias were identified (low risk)
(Merli 1994; O’Brien 1992).
Effects of interventions
See: Summary of findings for the main comparison
The authors of the two six-month trials have kindly provided us
with raw data (personal communication) (Merli 1994; O’Brien
1992). Where possible we have entered quantitative data, but the
use of complicated trial designs has meant that we have had to use
subsets of small sample sizes. In one cross-over trial it is unclear
whether there was any washout period employed and data are not
published for the first six-month period of the trial; therefore while
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we have listed the trial as included, we are not able to present any
results as we are unable to extract appropriate data (Lepage 1997).
Primary outcomes
1. Reduction of raised hepatocellular enzymes to within
normal range of the method stated
We wished to examine the effect of UDCA on abnormal liver
biochemistry by comparing the numbers of participants in both
groups whose liver enzymes fell to within the normal range of the
method stated at various time points. This was not reported as
an outcome measure in any of the three RCTs but, serving as a
proxy for this, the improvement in abnormalities of liver function
was measured in all three RCTs. Raw data were available from
two of the RCTs to enable us to examine this outcome (personal
communication) (Merli 1994; O’Brien 1992). We assessed this
outcome in three different ways (all with a very low quality of
evidence): normalisation of any liver enzyme reported, odds ratio
(OR) 0.09 (95% CI 0.01 to 1.24) (Analysis 1.1); normalisation
of all liver enzymes reported (OR not estimable as there were no
participants in either of the two trials with all enzymes normalised)
(Analysis 1.2); and normalisation of individual liver enzymes (OR
less than one for three out of four enzymes but the CIs were very
wide) (Analysis 1.3; Analysis 1.4; Analysis 1.5; Analysis 1.6). For
aspartate transaminase the OR was greater than one, again with a
wide CI (Analysis 1.4).
2. Reduction of abnormally large livers as measured by
ultrasound
The effect on liver size was not reported in any of the RCTs.
3. Liver transplantation
Need for liver transplantation was not specifically used as an out-
come measure in any of the RCTs. However, one trial reported
that one participant, who initially had multilobular cirrhosis and
oesophageal varices (advanced liver involvement) and was allo-
cated to treatment with UDCA, was subsequently withdrawn due
to further deterioration of liver function (Colombo 1996). This
participant proceeded to liver transplantation. However, the CI of
the OR generated was very wide and it was not possible to draw
any conclusions about the effect of UDCA on the need for trans-
plants (very low quality of evidence) (Analysis 1.7)
Need for liver transplantation was reported as an outcome in
the long-term follow-up data from the Colombo trial (Colombo
1996). Six participants underwent liver transplantation. However,
these long-term data were reported as follow up for the whole co-
hort, not by randomised group. Therefore, it is not possible to
draw any firm conclusions about the effect of UDCA therapy on
the need for liver transplantation from these data.
None of the participants in the two six-month trials required liver
transplants (personal communication) (very low quality of evi-
dence) (Merli 1994; O’Brien 1992) (Analysis 1.7).
Secondary outcomes
1. Mortality
Mortality was not reported in any of the RCTs (low quality of
evidence), but there were no deaths in the two six-month trials
(personal communication) (Merli 1994; O’Brien 1992) (Analysis
1.8; Analysis 1.9)
Mortality was presented in the long-term follow-up data of the
Colombo trial which reported 13 deaths; none of which were due
to liver disease (Colombo 1996). However, these long-term data
were reported for the whole cohort, not by randomised group.
Therefore, it is not possible to draw any firm conclusions about
the effect of UDCA therapy on mortality from these data.
2. Change in weight
Nutritional indices were one of only two pre-defined outcomes
reported in the published reports.Weight gainwas reported in only
one of the RCTs (O’Brien 1992). However, measures of weight
before and after six months’ treatment were reported in another
RCT (Merli 1994).
Using the raw data of weight measurements before and after treat-
ment or control in the two six-month trials (Merli 1994; O’Brien
1992), we calculated the weight change for each participant and
then themean and standard deviation for each trial (note: we again
used only 18 out of 51 participants in the cross-over trial (Merli
1994)); MD -0.90 kg (95% CI -1.94 to 0.14) (low quality of ev-
idence) (Analysis 1.10).
Skinfold thicknesswas reported in twoRCTs (Merli 1994;O’Brien
1992). Body mass percentile, which also takes into account the
population mean weight and height rather than body mass index
(weight in kilograms divided by height squared in metres), was
reported in one trial (Merli 1994). The available post-treatment
data (at six months) for the anthropometric outcomes reported in
the Merli and O’Brien papers are presented in the table below.
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Outcome measure Trial Result at 6 months (mean (SD))*
Ursodeoxycholic acid Control
Height (cm) Merli 1994 157 (12) 158 (12)
Body mass percentile Merli 1994 80.6 (7) 79.7 (6)
Triceps skinfold thickness
(mm)
Merli 1994 6.5 (2.1) 6.8 (2.3)
O’Brien 1992 10.0 (6.13) 12.1 (5.64)
Subscapular skinfold thickness
(mm)
O’Brien 1992 8.6 (2.94) 9.1 (4.41)
Mid-arm muscle circumference
(cm)
Merli 1994 19.8 (3.6) 20.0 (3.6)
O’Brien 1992 21.5 (3.19) 22.5 (1.96)
*O’Brien 1992 originally presented data as mean and standard
error. Standard errors were converted to standard deviations for
this table.
Merli additionally stated in the published paper that “Parameters
of fat deposits (TSF, BSF, SSF, ISF) and lean body mass (MAMC)
showed minor variations in both groups and were not influenced
by either treatment” (Merli 1994). O’Brien stated that “... weight
gain was associated with minor improvements in themeasured an-
thropometric parameters, i.e. mid-upper arm circumference, sub-
scapular skinfold thickness and triceps skinfold thickness in the
control group and mid upper arm circumference and subscapular
skinfold thickness in the treatment group. Only the improvement
in triceps skinfold thickness observed in the control group reached
statistical significance” (O’Brien 1992).
3. Development of portal hypertension (raised pressure in
the vein running through the liver) or its complications
These were not reported as outcome measures in any of the RCTs.
However, it was confirmed (personal communication) that in the
two six-month follow-up RCTs portal hypertension did not de-
velop in any of the participants (low quality of evidence) (Merli
1994; O’Brien 1992) (Analysis 1.11; Analysis 1.12).
4. Improvement of biliary excretion
This outcome was reported in only one trial (O’Brien 1992). The
original trial investigators measured the time (in minutes) from
injection of the isotope to maximal hepatic activity and the per-
centage clearance of isotope from the liver and biliary tree, at 45
and 60 minutes compared with maximal activity. No significant
changes in biliary excretion occurred after treatment with UDCA
(low quality of evidence).
D I S C U S S I O N
This systematic review was first conducted in 1995 and over the
intervening 22 years, no new meaningful clinical trial data have
become available to change the original conclusions.
Summary of main results
This first systematic review on the effectiveness of ursodeoxycholic
acid (UDCA) in cystic fibrosis (CF) highlights the paucity of ran-
domised controlled trials (RCTs). There have been no RCTs in-
vestigating UDCA for preventing the development of liver dis-
ease in people with CF. Disappointingly, the few RCTs carried out
have not adequately examined our pre-defined outcome measures,
but they do provide important preliminary information which re-
quires further evaluation. There was considerable variation in the
outcome measures examined in the three RCTs and in the time
points at which they were measured.
This review has shown the absence of any significant effects of
UDCA treatment on people with CF, apart from a slight effect on
the surrogate endpoint of reduction of raised liver enzymes to nor-
mal. The information received from the authors of the six-month
trials showed that no participants died, needed liver transplants
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or developed portal hypertension (Merli 1994; O’Brien 1992).
However, these are short-term trials and there is insufficient evi-
dence to show that UDCA improves survival or reduces the need
for liver transplantation. We failed to show a significant effect of
UDCA on weight change; but this is not the most appropriate
way of assessing change in nutritional status (see below). The only
trial that assessed the effect of UDCA on biliary excretion failed
to demonstrate any significant change after treatment (O’Brien
1992).
Although in our quantitative analysis we excluded data on partic-
ipants who also received taurine, we will briefly mention individ-
ual trial results. The Merli trial showed that a six-month period
of UDCA with or without taurine did not significantly affect the
nutritional status (Merli 1994), whilst Colombo failed to show an
effect of UDCA on liver enzymes (Colombo 1996).
Overall completeness and applicability of
evidence
It is difficult to draw any meaningful conclusions from these re-
sults which are taken from small numbers of participants. Fur-
thermore, several clinically meaningful outcomes, such as portal
hypertension, liver transplantation and survival were not assessed.
A number of surrogate endpoints have been reported; however, we
cannot be sure that these actually correlate with important end-
points. For example, there is no evidence of a clear correlation
between the serum level of hepatocellular enzymes and the degree
of liver disease.
Change in weight is not the most appropriate way of assessing
any change in nutritional status. This is because we would expect
children to gain weight over time, but expect the weight of adults
to remain stable. It would be more appropriate to use indices such
as body mass index or weight for height as a z score (where weight
is expressed as a percentage of ideal for height and then compared
with the standard deviation for the population).
In this reviewwehave included trialswith a non-homogenous pop-
ulation (Merli 1994) and have, therefore, considered both possible
preventative and therapeutic effects of UDCA in the same review.
As we cannot be sure how raised levels of certain liver enzymes
correlate with liver involvement (or whether absence of raised en-
zymes indicates a lack of liver involvement), we decided that we
would lose important information if this trial were excluded.
Quality of the evidence
Althoughwe hadnot specifically excluded cross-over trials, wewere
concerned about the use of a cross-over design. This was because
there may be a carry-over effect of UDCA in the control arm,
although the authors of the included cross-over trial attempted
to overcome this problem by using a one-month washout period.
However, we considered it appropriate to compare only the first
six months of the trial, i.e. UDCA versus placebo.
We were only able to perform a limited quantitative meta-analysis
due to the lack of data on clinically relevant endpoints and the
different time points at which outcomes weremeasured. However,
this systematic review provides an important summary of the in-
formation currently available from RCTs on the use of UDCA.
This information may be used to inform the design of subsequent
RCTs.
Overall, the quality of the evidence identified ranged from low to
very low (Summary of findings for the main comparison).
Potential biases in the review process
We have undertaken comprehensive searches, including attempts
to source unpublished data, to ensure that we have not failed to
identify any potentially eligible RCTs. The authors have indepen-
dently assessed the search results and extracted data in order to
minimise any possible errors.
Agreements and disagreements with other
studies or reviews
We have been unable to find any other similar reviews of UDCA
in CF or any further studies other than the ones we have already
included or excluded.
Although UCDA is often used for the prevention or treatment
of CF-related liver disease, recommendations from guidelines are
inconsistent and not based on robust evidence (CF Trust 2011;
CF Trust 2016; Debray 2011; Sokol 1999).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Although UDCA is relatively inexpensive compared to other CF
treatments, it would need to be taken on a long-term basis if it is
effective. If it is ineffective then the resources saved by not using
it could be used for other aspects of CF care.
Evidence of the effectiveness of UDCA is inconclusive. Routine
use of UDCA in people with CF cannot, therefore, be justified.
However, in view of these important preliminary results and be-
cause of the lack of any other effective intervention to prevent or
treat CF-related liver disease, it is essential that a large multicentre
RCT of UDCA in people with CF is undertaken.
Implications for research
The results of this systematic review indicate that there is an ur-
gent need for a well-designed, adequately powered, multicentre
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RCT assessing the effectiveness of UDCA by measuring clinically
relevant end points over years rather than months. Ideally a par-
allel trial, not a cross-over trial, should be undertaken. However,
as there is insufficient evidence to indicate that UDCA is effective
in CF, it is not possible to suggest how long it should be given,
but long-term end points need to be assessed. Future trials should
define the target population clearly, with separate trials for those
without clinically detectable liver disease (the preventative effect)
and those with liver disease (the therapeutic effect). In view of the
problems of defining and assessing progression of liver involve-
ment as well as the problem that by the time liver involvement
is detected, it is too advanced for treatment, we suggest that the
former is carried out first.
Althoughwe have not been able to perform a formalmeta-analysis,
the RCTs we have identified show important preliminary results.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Colombo 1996
Methods Multi-factorial (4 parallel groups: initial randomisation to UDCA or placebo, then tau-
rine or second placebo randomly added to participants), centrally computer-generated
list, double-blind.
Multicentre, 12 centres in Italy.
Participants Inclusion criteria: diagnosis of CF (sweat test and clinically) and chronic liver disease,
defined on basis of large liver, abnormal liver ultrasound showing increased liver size,
abnormal pattern and irregular surface, abnormal liver enzymes (serum transaminases
and gamma glutamyl transpeptidase for at least 12 months).
Participants excluded if any previous treatment with UDCA, less than 3 years, serum
bilirubin over 3 mg/dL, ascites, chronic viral hepatitis, co-existing severe lung disease,
previous episodes of bleeding from oesophageal varices or other complications of portal
hypertension.
55 (39 male) participants. 15 in UDCA and taurine group, 15 in UDCA and placebo
group, 12 in placebo and taurine group and 13 in placebo and placebo group. Age range
4 - 22 years (median 13.8 years).
All 5 participants with oesophageal varices and 7 out of 8 participants with abnormal
serum bilirubin levels at entry, in UDCA group
Interventions Length of therapy: 12 months
UDCA: 10 - 20 mg/kg/day.
Taurine: 17 - 33 mg/kg/day.
Control: placebo.
Outcomes Measured at 12 months
Shwachman-Kulczycki score (SKS), liver enzymes (gammaglutamate transferase, 5’ nu-
cleotidase, aspartate transaminase, alanine transaminase), prealbumin, daily faecal fat
excretion
Notes Follow-up data reported in 2005, but not split by treatment group, only reported for
whole cohort
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list.
Allocation concealment (selection bias) Low risk List generated centrally.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Described as double blind.
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Colombo 1996 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk An intention-to-treat analysis was per-
formed.
Other bias High risk Group characteristics not equal at baseline
- all 5 participants with oesophageal varices
and 7 out of 8 participants with abnormal
serum bilirubin levels at entry, in UDCA
group
Lepage 1997
Methods Double-blind, placebo-controlled, randomised cross-over trial 1 year duration (2 periods
of 6 months each)
Single centre in Canada.
Participants 19 (13 males; 6 girls) children with CF and liver dysfunction, aged 7 - 17 years (mean
(SD) 11.9 (0.6) years)
6 withdrawals (1 died, 4 moved away, 1 discontinued medication)
Interventions UDCA (15 mg/kg/day) versus placebo.
In the absence of a 50% decrease of ALT or AST or both within 2 months, the dose was
increased to 30 mg/kg
Participants received their usual medication, including pancreatic enzyme supplements
Outcomes Liver function tests (AST, ALT, GGT), plasma lipid levels (total fatty acids, triglycerides,
cholesterol), plasma RBP, transthyretin, retinol, retinyl ester levels
Notes Supported by a University-Industry (Jouveinal Inc.) award (UI- 0062), from theMedical
Research Council of Canada and by a grant from the Canadian Cystic Fibrosis Founda-
tion
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Paper states “randomly assigned” but gives
no further details
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not discussed.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 6/19 withdrew - 1 participant died, 4
moved away, and 1 discontinued his med-
ication
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Lepage 1997 (Continued)
Other bias Unclear risk Cross-over trial and data not presented for
each treatment arm separately. Not clear if
a washout period was employed
Merli 1994
Methods Cross-over design. Randomisation to UDCA or UDCA plus taurine for 6 months, then
each group compared with placebo for 6 months and sequence of treatment/placebo
randomised. Placebo was glucose.
Single centre. Italy.
Participants Inclusion criteria:
1. diagnosis of CF as documented by raised sweat chloride values and clinical
symptoms;
2. evidence of malnutrition as documented by body mass percentile less than or
equal to 90%;
3. age over 6 years;
4. good compliance with previous conventional treatment;
5. no previous UDCA treatment.
51 participants recruited, age range 8 - 32 years, median 14 years. 10 participants had
abnormal liver enzymes and of these 2 had cirrhosis and varices and 8 had enlarged liver
and fibrosis at ultrasound. 42 participants completed the trial, 9 dropouts (5 in UDCA
group, 4 in UDCA plus taurine group) not followed-up
Interventions UDCA: 12 mg/kg/day for 6 months (see Methods for trial design).
Taurine: 18 - 22 mg/kg/day for 6 months.
Control: placebo (glucose) for 6 months.
Outcomes Measured at 6 months
weight, body mass percentile, triceps skinfold thickness, mid-arm-muscle circumference,
albumin, AST, ALT, ALP, GGT
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated as randomised but no further details
of method given.
Allocation concealment (selection bias) Unclear risk Unclear.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Glucose tablets given as placebo, so partic-
ipants probably blinded, but not explicitly
stated
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Merli 1994 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 51 participants were initially recruited, but
9 subsequently withdrew (5 in UDCA
group, 4 in UDCA plus taurine group).
These participants were not followed up
and were not included in the analysis. Data
from a further 2 participants were identi-
fied as being lost when the raw data were
provided
Other bias Unclear risk None identified.
O’Brien 1992
Methods Randomisation stated - method not described.
Single centre. Ireland.
Participants Inclusion criteria: participants with CF (diagnosed by sweat test and clinically) and with
liver disease. This was defined as large liver, greater than 12 cm on physical examination
and/or large spleen, palpable on examination and confirmed by abdominal ultrasound
and/ or raised liver enzymes for at least 6 months (GGT above 50 IU/L, 5’nucleotidase
over 15 IU/l).
12 participants recruited. Age range 12 - 42 years (median 19.5 years). 11 out of 12
participants had advanced liver disease - portal hypertension and/or histological features
of fibrosis or cirrhosis
Interventions UDCA: 20 mg/kg/day for 6 months.
Control: No additional therapy.
Outcomes Weight gain, triceps skinfold thickness, mid-upper arm circumference, subscapular skin-
fold thickness, liver enzymes, biliary excretion
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation stated - method not de-
scribed.
Allocation concealment (selection bias) Low risk Sealed envelopes used.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Control was no additional therapy so clini-
cians andparticipants could not be blinded,
not discussed whether outcome assessors
were blinded
20Ursodeoxycholic acid for cystic fibrosis-related liver disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
O’Brien 1992 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk An intention-to-treat analysis was per-
formed.
Other bias Unclear risk None identified.
ALP: alkaline phosphatase
ALT: alanine transaminase
AST: aspartate transaminase
CF: cystic fibrosis
GGT: gamma glutamate transferase
IU/L: international unit per litre
RBP: retinol binding protein
UDCA: ursodeoxycholic acid
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bittner 1989 Unclear how long UDCA given for, follow up only 6 weeks.
Colombo 1992 Comparison of different doses of UDCA rather than with placebo or conventional therapy
Kapustina 2000 Only published as an abstract (no full paper) with insufficient detail to confirm it meets the inclusion
criteria; given the age of the abstract, it is unlikely that any further publications relating to this trial will be
forthcoming
Narckewicz 1994 Multi-period, multi-treatment trial, not randomised.
NCT00004315 Cross-over trial where each treatment arm only given for 4 weeks
NCT00004441 Not a valid comparison - active group is tauro-ursodeoxcholic acid and the comparator is ursodeoxycholic
acid. Our inclusion criteria state that the active treatment is UDCA with the control group receiving either
placebo or no additional therapy
Spray 2000 Only published as an abstract (no full paper) with insufficient detail to confirm it meets the inclusion
criteria; given the age of the abstract, it is unlikely that any further publications relating to this trial will be
forthcoming
Van de Meeberg 1997 Comparison of low dose UDCA (10 mg/kg/day) versus high dose UDCA (20 mg/kg/day) rather than
UDCA against placebo or no additional treatment
UDCA: ursodeoxycholic acid
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D A T A A N D A N A L Y S E S
Comparison 1. UDCA versus placebo/no additional treatment (all groups given ’conventional care’)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Lack of normalisation of any
liver enzyme reported in the
trial
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 6 months 2 16 Odds Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 1.24]
2 Lack of normalisation of all liver
enzymes reported in the trial
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 6 months 2 16 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Lack of normalisation of 5’
nucleotidase
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 6 months 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Lack of normalisation of
aspartate transaminase
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 6 months 2 14 Odds Ratio (M-H, Fixed, 95% CI) 11.0 [0.43, 284.30]
5 Lack of normalisation of alanine
transferase
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 6 months 2 12 Odds Ratio (M-H, Fixed, 95% CI) 0.41 [0.04, 4.01]
6 Lack of normalisation of
gammaglutamate transferase
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 6 months 2 10 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.02, 6.65]
7 Need for liver transplantation 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 0 to 6 months 2 30 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 7 to 12 months 1 28 Odds Ratio (M-H, Fixed, 95% CI) 2.79 [0.10, 74.63]
8 Death related to liver disease 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 0 to 6 months 2 30 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 7 to 12 months 1 28 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Death due to all causes 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 0 to 6 months 2 30 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 7 to 12 months 1 28 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Change in weight (kg) 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 0 to 6 months 2 30 Mean Difference (IV, Fixed, 95% CI) -0.90 [-1.94, 0.14]
11 Development of portal
hypertension
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 0 to 6 months 2 30 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.2 7 to 12 months 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Development of complications
of portal hypertension
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 0 to 6 months 2 30 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.2 7 to 12 months 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 UDCA versus placebo/no additional treatment (all groups given ’conventional
care’), Outcome 1 Lack of normalisation of any liver enzyme reported in the trial.
Review: Ursodeoxycholic acid for cystic fibrosis-related liver disease
Comparison: 1 UDCA versus placebo/no additional treatment (all groups given ’conventional care’)
Outcome: 1 Lack of normalisation of any liver enzyme reported in the trial
Study or subgroup UDCA Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 months
Merli 1994 0/2 2/2 47.3 % 0.04 [ 0.00, 2.93 ]
O’Brien 1992 0/6 2/6 52.7 % 0.14 [ 0.01, 3.63 ]
Subtotal (95% CI) 8 8 100.0 % 0.09 [ 0.01, 1.24 ]
Total events: 0 (UDCA), 4 (Control)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.80 (P = 0.072)
0.001 0.01 0.1 1 10 100 1000
Favours UDCA Favours Control
Analysis 1.2. Comparison 1 UDCA versus placebo/no additional treatment (all groups given ’conventional
care’), Outcome 2 Lack of normalisation of all liver enzymes reported in the trial.
Review: Ursodeoxycholic acid for cystic fibrosis-related liver disease
Comparison: 1 UDCA versus placebo/no additional treatment (all groups given ’conventional care’)
Outcome: 2 Lack of normalisation of all liver enzymes reported in the trial
Study or subgroup UDCA Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 months
Merli 1994 2/2 2/2 Not estimable
O’Brien 1992 6/6 6/6 Not estimable
Subtotal (95% CI) 8 8 Not estimable
Total events: 8 (UDCA), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Favours UDCA Favours control
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Analysis 1.3. Comparison 1 UDCA versus placebo/no additional treatment (all groups given ’conventional
care’), Outcome 3 Lack of normalisation of 5’ nucleotidase.
Review: Ursodeoxycholic acid for cystic fibrosis-related liver disease
Comparison: 1 UDCA versus placebo/no additional treatment (all groups given ’conventional care’)
Outcome: 3 Lack of normalisation of 5’ nucleotidase
Study or subgroup UDCA Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 months
O’Brien 1992 3/5 3/4 0.50 [ 0.03, 8.95 ]
0.02 0.1 1 10 50
Favours UDCA Favours control
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Analysis 1.4. Comparison 1 UDCA versus placebo/no additional treatment (all groups given ’conventional
care’), Outcome 4 Lack of normalisation of aspartate transaminase.
Review: Ursodeoxycholic acid for cystic fibrosis-related liver disease
Comparison: 1 UDCA versus placebo/no additional treatment (all groups given ’conventional care’)
Outcome: 4 Lack of normalisation of aspartate transaminase
Study or subgroup UDCA Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 months
Merli 1994 1/1 2/2 Not estimable
O’Brien 1992 5/5 3/6 100.0 % 11.00 [ 0.43, 284.30 ]
Subtotal (95% CI) 6 8 100.0 % 11.00 [ 0.43, 284.30 ]
Total events: 6 (UDCA), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
0.001 0.01 0.1 1 10 100 1000
Favours UDCA Favours control
Analysis 1.5. Comparison 1 UDCA versus placebo/no additional treatment (all groups given ’conventional
care’), Outcome 5 Lack of normalisation of alanine transferase.
Review: Ursodeoxycholic acid for cystic fibrosis-related liver disease
Comparison: 1 UDCA versus placebo/no additional treatment (all groups given ’conventional care’)
Outcome: 5 Lack of normalisation of alanine transferase
Study or subgroup UDCA Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 months
Merli 1994 0/2 1/1 62.8 % 0.07 [ 0.00, 5.49 ]
O’Brien 1992 4/6 2/3 37.2 % 1.00 [ 0.05, 18.91 ]
Subtotal (95% CI) 8 4 100.0 % 0.41 [ 0.04, 4.01 ]
Total events: 4 (UDCA), 3 (Control)
Heterogeneity: Chi2 = 1.00, df = 1 (P = 0.32); I2 =0%
Test for overall effect: Z = 0.76 (P = 0.45)
0.001 0.01 0.1 1 10 100 1000
Favours UDCA Favours control
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Analysis 1.6. Comparison 1 UDCA versus placebo/no additional treatment (all groups given ’conventional
care’), Outcome 6 Lack of normalisation of gammaglutamate transferase.
Review: Ursodeoxycholic acid for cystic fibrosis-related liver disease
Comparison: 1 UDCA versus placebo/no additional treatment (all groups given ’conventional care’)
Outcome: 6 Lack of normalisation of gammaglutamate transferase
Study or subgroup UDCA Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6 months
Merli 1994 0/1 0/1 Not estimable
O’Brien 1992 2/5 2/3 100.0 % 0.33 [ 0.02, 6.65 ]
Subtotal (95% CI) 6 4 100.0 % 0.33 [ 0.02, 6.65 ]
Total events: 2 (UDCA), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
0.02 0.1 1 10 50
Favours UDCA Favours control
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Analysis 1.7. Comparison 1 UDCA versus placebo/no additional treatment (all groups given ’conventional
care’), Outcome 7 Need for liver transplantation.
Review: Ursodeoxycholic acid for cystic fibrosis-related liver disease
Comparison: 1 UDCA versus placebo/no additional treatment (all groups given ’conventional care’)
Outcome: 7 Need for liver transplantation
Study or subgroup UDCA Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 0 to 6 months
Merli 1994 0/6 0/12 Not estimable
O’Brien 1992 0/6 0/6 Not estimable
Subtotal (95% CI) 12 18 Not estimable
Total events: 0 (UDCA), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 7 to 12 months
Colombo 1996 1/15 0/13 100.0 % 2.79 [ 0.10, 74.63 ]
Subtotal (95% CI) 15 13 100.0 % 2.79 [ 0.10, 74.63 ]
Total events: 1 (UDCA), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
0.01 0.1 1 10 100
Favours UDCA Favours control
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Analysis 1.8. Comparison 1 UDCA versus placebo/no additional treatment (all groups given ’conventional
care’), Outcome 8 Death related to liver disease.
Review: Ursodeoxycholic acid for cystic fibrosis-related liver disease
Comparison: 1 UDCA versus placebo/no additional treatment (all groups given ’conventional care’)
Outcome: 8 Death related to liver disease
Study or subgroup UDCA Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 0 to 6 months
Merli 1994 0/6 0/12 Not estimable
O’Brien 1992 0/6 0/6 Not estimable
Subtotal (95% CI) 12 18 Not estimable
Total events: 0 (UDCA), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 7 to 12 months
Colombo 1996 0/15 0/13 Not estimable
Subtotal (95% CI) 15 13 Not estimable
Total events: 0 (UDCA), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Favours UDCA Favours control
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Analysis 1.9. Comparison 1 UDCA versus placebo/no additional treatment (all groups given ’conventional
care’), Outcome 9 Death due to all causes.
Review: Ursodeoxycholic acid for cystic fibrosis-related liver disease
Comparison: 1 UDCA versus placebo/no additional treatment (all groups given ’conventional care’)
Outcome: 9 Death due to all causes
Study or subgroup UDCA Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 0 to 6 months
Merli 1994 0/6 0/12 Not estimable
O’Brien 1992 0/6 0/6 Not estimable
Subtotal (95% CI) 12 18 Not estimable
Total events: 0 (UDCA), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 7 to 12 months
Colombo 1996 0/15 0/13 Not estimable
Subtotal (95% CI) 15 13 Not estimable
Total events: 0 (UDCA), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours UDCA Favours control
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Analysis 1.10. Comparison 1 UDCA versus placebo/no additional treatment (all groups given ’conventional
care’), Outcome 10 Change in weight (kg).
Review: Ursodeoxycholic acid for cystic fibrosis-related liver disease
Comparison: 1 UDCA versus placebo/no additional treatment (all groups given ’conventional care’)
Outcome: 10 Change in weight (kg)
Study or subgroup UDCA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 0 to 6 months
Merli 1994 6 0.07 (0.62) 12 0.83 (1.68) 94.7 % -0.76 [ -1.83, 0.31 ]
O’Brien 1992 6 1.48 (4.83) 6 4.88 (2.98) 5.3 % -3.40 [ -7.94, 1.14 ]
Subtotal (95% CI) 12 18 100.0 % -0.90 [ -1.94, 0.14 ]
Heterogeneity: Chi2 = 1.23, df = 1 (P = 0.27); I2 =19%
Test for overall effect: Z = 1.69 (P = 0.091)
-4 -2 0 2 4
Favours UDCA Favours treatment
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Analysis 1.11. Comparison 1 UDCA versus placebo/no additional treatment (all groups given ’conventional
care’), Outcome 11 Development of portal hypertension.
Review: Ursodeoxycholic acid for cystic fibrosis-related liver disease
Comparison: 1 UDCA versus placebo/no additional treatment (all groups given ’conventional care’)
Outcome: 11 Development of portal hypertension
Study or subgroup UDCA Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 0 to 6 months
Merli 1994 0/6 0/12 Not estimable
O’Brien 1992 0/6 0/6 Not estimable
Subtotal (95% CI) 12 18 Not estimable
Total events: 0 (UDCA), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 7 to 12 months
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (UDCA), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Favours UDCA Favours control
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Analysis 1.12. Comparison 1 UDCA versus placebo/no additional treatment (all groups given ’conventional
care’), Outcome 12 Development of complications of portal hypertension.
Review: Ursodeoxycholic acid for cystic fibrosis-related liver disease
Comparison: 1 UDCA versus placebo/no additional treatment (all groups given ’conventional care’)
Outcome: 12 Development of complications of portal hypertension
Study or subgroup UDCA Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 0 to 6 months
Merli 1994 0/6 0/12 Not estimable
O’Brien 1992 0/6 0/6 Not estimable
Subtotal (95% CI) 12 18 Not estimable
Total events: 0 (UDCA), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 7 to 12 months
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (UDCA), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Favours UDCA Favours control
WH A T ’ S N E W
Date Event Description
1 August 2017 New search has been performed A search of the Cystic Fibrosis and Genetic Disor-
ders Review Group’s Cystic Fibrosis Trials Register iden-
tified a single additional reference to an already ex-
cluded trial (Colombo 1992). Searches of ongoing tri-
als registries identified two trials which were excluded
(NCT00004315; NCT00004441).
Three trials were previously listed as ’Studies awaiting
classification’ pending further information from the au-
thors which we have not been able to access (Kapustina
2000; Lepage 1997; Spray 2000). Two of these trials have
never been published as full papers and the abstracts do
not contain sufficient details for us to confirm they meet
the inclusion criteria; given the age of the abstracts, it is
unlikely that any further publications relating to these
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(Continued)
trials will be forthcoming and they have therefore been
excluded (Kapustina 2000; Spray 2000). The third trial
is cross-over in design but it is unclear whether there was
any washout period employed and data are not published
for the first six-month period of the trial (Lepage 1997)
. We have added the study to the list of included trials,
but have not been able to present any results as we are
unable to extract appropriate data to analyse
A summary of findings table has been included.
1 August 2017 New citation required but conclusions have not changed No new data have been added to this review and hence
our conclusions remain the same
H I S T O R Y
Date Event Description
4 December 2014 New search has been performed A search of the Cystic Fibrosis & Genetic Disorders
Review Groups’ Cystic Fibrosis Trials Register did not
identify any new references for inclusion in this review.
The format of the plain language summary has been
updated
4 December 2014 New citation required but conclusions have not
changed
No new information has been added to this review,
hence our conclusions remain the same
24 January 2013 Amended Contact details updated.
12 September 2012 New citation required but conclusions have not
changed
No new references have been included in this update
of the review and hence the conclusions of the review
remain the same
12 September 2012 New search has been performed A new search of the Group’s Cystic Fibrosis Trials Reg-
ister did not identify any new references potentially
eligible for inclusion in this review
12 August 2010 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
did not identify any new studies for inclusion in this
review
4 February 2009 Amended Contact details for Deborah Ashby updated
11 November 2008 New search has been performed A search of the Group’s Cystic Fibrosis Trials register
did not identify any references which may have been
eligible for inclusion in this review
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11 November 2008 Amended Converted to new review format.
23 May 2007 New search has been performed The Cochrane Cystic Fibrosis and Genetic Disorders
Group Trials Register was searched in November 2006
and an additional reference concerning long-term fol-
low-up data to the already included Colombo trial was
identified. Follow-up data were only reported for the
whole cohort
15 February 2006 New search has been performed The Cochrane Cystic Fibrosis and Genetic Disorders
Group Trials Register was searched in November 2005
No new references were identified in the search.
16 February 2005 New search has been performed The Cochrane Cystic Fibrosis and Genetic Disorders
Group Trials Register was searched in November 2004
No new references were identified in the search.
18 February 2004 New search has been performed The Cochrane Cystic Fibrosis and Genetic Disorders
Group Trials Register was searched in October 2003.
No new references were identified in the search
19 February 2003 Amended In January 2003, minor statistical amendments to the
data from the O’Brien 1992 and Merli 1994 trials
were made. The means and standard deviations were
originally calculated by the reviewer from the original
published data, but a minor error was highlighted by
the Group’s medical statistician and the appropriate
corrections undertaken
22 May 2002 New search has been performed The Cochrane Cystic Fibrosis and Genetic Disorders
Group Trials Register was searched in April 2002, but
no new references were identified in the search
1 May 1999 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Katharine Cheng and Rosalind Smyth independently assessed trials for inclusion in the review. Katharine Cheng wrote the text of the
review, assisted by Rosalind Smyth, and acts as guarantor of the review.
Deborah Ashby provided statistical advice.
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D E C L A R A T I O N S O F I N T E R E S T
The lead author of this review, Katharine Cheng, has been employed by GlaxoSmithKline Research and Development Ltd since late
2004. GlaxoSmithKline does not produce or market any drugs that may fall into the scope of this review.
Deborah Ashby and Rosalind Smyth declare no potential conflicts of interest.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• NHS North West Region R&D Programme, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In a post hoc change, in line with current Cochrane guidance, at the 2017 update we added a summary of findings table with seven
outcomes chosen based on relevance to clinicians and consumers.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Bile [secretion]; Cholagogues andCholeretics [∗therapeutic use]; ChronicDisease; Cystic Fibrosis [∗complications]; Liver [enzymology];
Liver Diseases [etiology; ∗prevention & control]; Randomized Controlled Trials as Topic; Ursodeoxycholic Acid [∗therapeutic use]
MeSH check words
Adolescent; Adult; Child; Child, Preschool; Humans
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